Highlights: Myeloma Oral Session

Slides:



Advertisements
Similar presentations
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Advertisements

A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
The reading is 7.38 mm. The reading is 7.72 mm.
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Presented By Sham Mailankody at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
Securing the cure in resectable lung cancer
Presented By Luca Malorni at 2017 ASCO Annual Meeting
continued on next slide
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
                                                                                                                                                                                                                                                
continued on next slide
continued on next slide
Presented By James Rubenstein at 2016 ASCO Annual Meeting
Rossi A et al. Proc ASCO 2011;Abstract 8008.
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired. 1.
Palumbo A et al. Proc ASCO 2011;Abstract 8007.
Advances in Multiple Myeloma
Optimizing Frontline Care for Older Patients With Multiple Myeloma
Choose the best answer for each problem.
Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.
Presented By Praful Ravi at 2016 ASCO Annual Meeting
Approaches in Newly Diagnosed Multiple Myeloma: When and What
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired. 1.
Staying Abreast of Best Practices Across the Clinical Continuum
Managing Multiple Myeloma in the Elderly
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
Presented By Steven Park at 2016 ASCO Annual Meeting
A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.
On the Cusp: New Approaches for Multiple Myeloma
You may choose to use any one of these provide slide templates and make changes as desired. 1.
You may choose to use any one of these provide slide templates and make changes as desired.
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
You may choose to use any one of these provide slide templates and make changes as desired. 1.
You may choose to use any one of these provide slide templates and make changes as desired.
The Changing Goals of CML Therapy
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
continued on next slide
Presented By Joshua Richter at 2016 ASCO Annual Meeting
Presented By Andrew Evens at 2016 ASCO Annual Meeting
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
You may choose to use any one of these provide slide templates and make changes as desired.
continued on next slide
Presentation transcript:

Highlights: Myeloma Oral Session Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Learning Objectives Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting The Context Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting The Challenges Presented By Saad Usmani at 2014 ASCO Annual Meeting

Optimal Treatment for Newly Diagnosed MM Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Slide 6 Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Slide 7 Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Slide 8 Presented By Saad Usmani at 2014 ASCO Annual Meeting

Choosing Therapy for RRMM Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Approach to RRMM Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Slide 11 Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Slide 12 Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Slide 13 Presented By Saad Usmani at 2014 ASCO Annual Meeting

Presented By Saad Usmani at 2014 ASCO Annual Meeting Conclusions Presented By Saad Usmani at 2014 ASCO Annual Meeting